2017). This implies that the reduction in plasma glucose profiles after phlorizin pre‐treatment (Fig. 3), is, at least in part, due to excretion of glucose into the urine. This is the basis for the SGLT2 inhibitors used to treat diabetes (Gallo et al. 2015; Ghezzi et al. 2017). The gene discussed is SLC5A2; the disease is diabetes mellitus.